IMMUNITYBIO, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price
IMMUNITYBIO, INC. (IBRX) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price of $5.68 per share as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice · last filed 2026-08-04
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price $5.68.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price $5.83.
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price $6.70.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price $6.69.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price |
|---|---|
| 2026-06-30 | $5.68 10-Q · filed 2026-08-04 |
| 2026-03-31 | $5.83 10-Q · filed 2026-05-07 |
| 2025-12-31 | $6.70 10-K · filed 2026-02-23 |
| 2025-09-30 | $6.69 10-Q · filed 2025-11-05 |
| 2025-06-30 | $9.07 10-Q · filed 2025-08-05 |
| 2025-03-31 | $9.08 10-Q · filed 2025-05-12 |
| 2024-12-31 | $10.39 10-K · filed 2025-03-03 |
| 2024-09-30 | $10.38 10-Q · filed 2024-11-12 |
| 2024-06-30 | $10.20 10-Q · filed 2024-08-12 |
| 2024-03-31 | $10.98 10-Q · filed 2024-05-09 |
| 2023-12-31 | $11.54 10-K · filed 2024-03-19 |
| 2023-09-30 | $11.53 10-Q · filed 2023-11-09 |
| 2023-06-30 | $11.38 10-Q · filed 2023-08-08 |
| 2023-03-31 | $12.93 10-Q · filed 2023-05-11 |
| 2022-12-31 | $14.75 10-K · filed 2023-03-01 |
| 2022-09-30 | $14.70 10-Q · filed 2022-11-09 |
| 2022-06-30 | $14.70 10-Q · filed 2022-08-08 |
| 2022-03-31 | $14.66 10-Q · filed 2022-05-10 |
| 2021-12-31 | $13.89 10-K · filed 2022-03-01 |
| 2021-09-30 | $13.78 10-Q · filed 2021-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |